Image

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Recruiting
2-75 years
All
Phase N/A

Powered by AI

Overview

RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.

RACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.

Mathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.

Description

RACSMEI is a nationwide, One Health, multi-pathogen initiative designed to generate integrated evidence for public-health decision-making in Cambodia. Beyond producing epidemiological findings, the project will establish a structured biobank and curated datasets intended to support long-term collaborative research, knowledge sharing, and evidence-informed policy. The program includes capacity building and technology transfer to strengthen national institutions and foster regional scientific leadership and international collaboration. Engagement with communities and national stakeholders is planned to facilitate future studies and promote the uptake of results in practice. Overall, RACSMEI aims to provide a scalable model for integrated infectious-disease assessment in low- and middle-income settings, creating durable infrastructure, partnerships, and decision-support resources that can be used beyond the project period.

Eligibility

Inclusion Criteria:

  • Residency in the village for more than 6 months;
  • Age between 2 and 75 years old at the time of inclusion;
  • For adults: provision of written consent;
  • For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;

Exclusion Criteria:

  • Unable to understand or consent;
  • Under guardianship or deprived of liberty;
  • Medical conditions that impede survey participation;
  • Refusal to participate in the study.

Study details
    Dengue
    Chikungunya
    Zika Virus Infection
    Japanese Encephalitis
    West Nile Virus
    Tick-borne Encephalitis (TBE)
    Severe Fever With Thrombocytopenia Syndrome
    Nipah Virus Infection
    Hantavirus Infections
    Hepatitis E
    Brucellosis
    Q Fever
    Leptospirosis
    Melioidosis
    Influenza A and B
    Malaria
    Yellow Fever
    Mayaro Fever
    Usutu Virus Infection
    Oropouche Fever
    Rift Valley Fever
    Arenavirus Infections
    Measles
    Mumps
    Rubella
    Human Papilloma Virus (HPV)
    Rotavirus Disease
    Pertussis
    Diphteria
    Tetanus
    Varicella
    Hepatitis A
    Norovirus Infections
    Enterovirus
    Adenovirus
    Rhinovirus
    Parvovirus
    Respiratory Syncytial Virus (RSV)
    Cytomegalovirus
    Epstein Barr Virus
    Salmonella Typhi
    Vibrio Cholerae
    Legionella Pneumophila Pneumonia
    Mycoplasma
    Chlamydia
    Lymphatic Filariasis
    Toxoplasma Gondii
    Giardiasis
    Entamoeba Histolytica
    Leishmaniasis
    Strongyloides Stercoralis Infection
    Ascaris Lumbricoides
    Trichuris Trichiura
    Clonorchis Sinensis
    Opisthorchis Viverrini
    Schistosomiasis
    Streptococcus Pneumoniae
    Meningitis

NCT07358910

Institut Pasteur du Cambodge

1 February 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.